|1.||Frenette, A J: 1 article (11/2014)|
|2.||Archambault, P M: 1 article (11/2014)|
|3.||Godwin, J: 1 article (11/2014)|
|4.||Juurlink, D N: 1 article (11/2014)|
|5.||Dubé, P-A: 1 article (11/2014)|
|6.||Blais, R: 1 article (11/2014)|
|7.||Le Sage, N: 1 article (11/2014)|
|8.||St-Onge, M: 1 article (11/2014)|
|9.||Provencher, J: 1 article (11/2014)|
|10.||Chauny, J-M: 1 article (11/2014)|
05/01/1979 - "Protective effect of prenylamine against vulnerability to ventricular fibrillation in the normal and ischemic canine myocardium."
07/31/1976 - "[Long QT, syncope caused by atypical ventricular fibrillation and chronic ingestion of prenylamine (review of the literature and report of a case]."
07/01/1967 - "Control of ventricular fibrillation during induced hypothermia in cats after differential depletion of cardiac catecholamine stores with prenylamine (Segontin)."
09/01/1984 - "Death was due in prenylamine-treated rats to atrioventricular block leading to asystole whereas in those administered verapamil or flunarizine it was a consequence of persistent ventricular fibrillation. "
01/01/1985 - "Thus, inhibition of the fast inward sodium channel with agents such as prenylamine and lignocaine, (when begun before coronary-artery occlusion) offers maximal protection against reperfusion-induced ventricular fibrillation, while beta-blockade with timolol and oxprenolol and slow calcium channel inhibition with nifedipine do not offer any significant protection. "
02/01/1981 - "[Management of chronic urticaria with prenylamine]."
03/01/1983 - "[Results of treatment of chronic urticaria with prenylamine]."
05/11/1980 - "[Treatment of chronic urticaria with Corontin forte]."
01/01/1985 - "This study was performed to re-evaluate the clinical position of prenylamine in the management of angina pectoris. "
07/01/1971 - "A double-blind, double cross-over trial of prenylamine in angina pectoris."
12/01/1970 - "A 2-year study of the efficacy and tolerability of prenylamine in the treatment of angina pectoris."
11/01/1980 - "The effect of prenylamine on the QT interval of the resting electrocardiogram in patients with angina pectoris."
09/01/1968 - "Effect of prenylamine in angina pectoris."
|4.||Coronary Disease (Coronary Heart Disease)
11/26/1976 - "Moreover, Segontin 60 mg is the preparation of choice if the coronary heart disease is accompanied by tachyarrhythmic and hyperkinetic symptoms."
11/26/1976 - "62 patients with coronary heart disease were treated with Segontin 60 mg for periods of 6 months to 8 years in a specialist internal medical practice. "
11/26/1976 - "[Longterm treatment of coronary heart disease with Segontin (author's transl)]."
03/31/1973 - "[Prenylamine in the therapy of coronary disease]."
04/15/1966 - "[Corontin in coronary disease]."
05/01/1977 - "5. Low concentrations of prenylamine (0.05 mM) which produced neither contracture, 45Ca efflux nor 45Ca influx, depressed the action potential, muscle twitch and K+ contracture. "
05/01/1977 - "4. Prenylamine produced a sustained increase in 45Ca efflux at all concentrations that produce contracture. "
05/01/1977 - "Pretreatment with 100 mM K+ blocked the phasic but not the tonic component of the prenylamine contracture. "
05/01/1977 - "2. Prenylamine (0.2-1.0 mM) produced a biphasic contracture in skeletal muscle characterized by an initial phasic and subsequent tonic contracture. "
05/01/1977 - "Prenylamine-induced contracture of frog skeletal muscle."
|2.||Calcium Channels (Calcium Channel)
|4.||Sodium Channels (Sodium Channel)
|4.||Medication Errors (Medication Error)